Inter-observer agreement of baseline whole body MRI in multiple myeloma.
Bone disease
Diffusion weighted imaging
Inter-observer agreement
MRI
Magnetic resonance imaging
Multiple myeloma
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
14 Jul 2020
14 Jul 2020
Historique:
received:
01
08
2019
accepted:
08
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Whole body magnetic resonance imaging (MRI) is now incorporated into international guidance for imaging patients with multiple myeloma. The aim of this study was to investigate inter-observer agreement of triple reported baseline whole-body MRI in myeloma and highlight potential pitfalls. Fifty-seven patients with symptomatic myeloma at first presentation or relapse and planned for autologous stem cell transplant were included. All patients completed baseline whole body MRI within 2 weeks prior to starting treatment. Each scan was reported independently by 3 radiologists using a defined scoring system. Differences in observer scores were compared using analysis of variance (ANOVA) and inter-observer agreement assessed using intra class correlation coefficient (ICC). There was no significant difference in mean observer scores for whole skeleton and ICC demonstrated excellent inter-observer agreement at 0.91. ICC varied between skeletal regions with spine, pelvis and ribs showing good inter-observer agreement, whereas skull and long bones were moderate. Scans with variation in observer scores were re-examined and cause of discrepancies identified. This information was used to describe potential anatomical pitfalls in reporting . Whole-body MRI has excellent inter-observer agreement in reporting symptomatic myeloma at baseline. Inter-observer agreement varied between skeletal regions highlighting specific areas of difficulty.
Sections du résumé
BACKGROUND
BACKGROUND
Whole body magnetic resonance imaging (MRI) is now incorporated into international guidance for imaging patients with multiple myeloma. The aim of this study was to investigate inter-observer agreement of triple reported baseline whole-body MRI in myeloma and highlight potential pitfalls.
METHODS
METHODS
Fifty-seven patients with symptomatic myeloma at first presentation or relapse and planned for autologous stem cell transplant were included. All patients completed baseline whole body MRI within 2 weeks prior to starting treatment. Each scan was reported independently by 3 radiologists using a defined scoring system. Differences in observer scores were compared using analysis of variance (ANOVA) and inter-observer agreement assessed using intra class correlation coefficient (ICC).
RESULTS
RESULTS
There was no significant difference in mean observer scores for whole skeleton and ICC demonstrated excellent inter-observer agreement at 0.91. ICC varied between skeletal regions with spine, pelvis and ribs showing good inter-observer agreement, whereas skull and long bones were moderate. Scans with variation in observer scores were re-examined and cause of discrepancies identified. This information was used to describe potential anatomical pitfalls in reporting .
CONCLUSION
CONCLUSIONS
Whole-body MRI has excellent inter-observer agreement in reporting symptomatic myeloma at baseline. Inter-observer agreement varied between skeletal regions highlighting specific areas of difficulty.
Identifiants
pubmed: 32665028
doi: 10.1186/s40644-020-00328-9
pii: 10.1186/s40644-020-00328-9
pmc: PMC7362571
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Références
Leukemia. 2013 Apr;27(4):947-53
pubmed: 23183429
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
Clin Radiol. 2015 Jun;70(6):614-21
pubmed: 25799364
Radiology. 2014 Jun;271(3):785-94
pubmed: 24475858
Leukemia. 2014 Sep;28(9):1902-8
pubmed: 24535407
Leukemia. 2016 Jun;30(6):1446-8
pubmed: 26648535
Magn Reson Imaging Clin N Am. 2018 Nov;26(4):509-525
pubmed: 30316464
N Engl J Med. 2013 Aug 1;369(5):438-47
pubmed: 23902483
Blood. 2017 Jul 6;130(1):30-34
pubmed: 28432222
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Haematologica. 2015 Jun;100(6):818-25
pubmed: 25795721
Br J Haematol. 2017 Aug;178(3):380-393
pubmed: 28677897
Am Soc Clin Oncol Educ Book. 2016;35:e418-23
pubmed: 27249749
J Clin Oncol. 2015 Feb 20;33(6):657-64
pubmed: 25605835
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61
pubmed: 28453614
Br J Radiol. 2012 Dec;85(1020):e1198-203
pubmed: 23175485
Radiology. 2019 Apr;291(1):5-13
pubmed: 30806604
Ann Oncol. 2005 Nov;16(11):1824-8
pubmed: 16087694
Br J Haematol. 2015 Oct;171(1):29-37
pubmed: 26013304